Souhaitez-vous accéder aux communiqués récents ?

Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph...

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Sydney, Australia, May 25, 2026 (GLOBE NEWSWIRE) -- Fixed-term accounts have been a familiar feature of the Australian savings landscape for decades, characterised by a defined investment period, a...

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth

Sydney, Australia, May 22, 2026 (GLOBE NEWSWIRE) -- Australian savers and income-focused investors are navigating an environment of higher interest rates and persistent inflation. On 5 May 2026, the...

Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic...

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients...

BioNTech SE will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at ASCO 2026.